SANIONA AB (PUBL) Total Liabilities
SANIONA AB (PUBL) total liabilities. Based on the latest financial reports, SANIONA AB (PUBL) (30S) has total liabilities worth €44.58 Million EUR (≈ $52.12 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See operational self-sufficiency of SANIONA AB (PUBL) to measure how many days the company can operate on defensive assets alone.
Total Liabilities of SANIONA AB (PUBL) (2021–2025)
Total liabilities of SANIONA AB (PUBL) from 2021 to 2025. This chart illustrates how SANIONA AB (PUBL)'s total liabilities have evolved over time, based on quarterly financial data.
SANIONA AB (PUBL) Competitors by Total Liabilities
The table below lists competitors of SANIONA AB (PUBL) ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Paramount Corporation Bhd
KLSE:1724
|
Malaysia | RM1.76 Billion |
|
Welldone Co
TWO:6170
|
Taiwan | NT$3.35 Billion |
|
TGE Value Creative Solutions Corp
NYSE:BEBE
|
USA | $563.84K |
|
Nine Energy Service, Inc.
NYSE:NINE
|
USA | $468.66 Million |
|
Segro Plc
LSE:SGRO
|
UK | GBX6.04 Billion |
|
PIE Industrial Bhd
KLSE:7095
|
Malaysia | RM165.48 Million |
|
APCB Inc
TW:6108
|
Taiwan | NT$4.25 Billion |
|
Meghmani Organics Limited
NSE:MOL
|
India | Rs-15.45 Billion |
Liability Composition Analysis (2021–2025)
This chart breaks down SANIONA AB (PUBL)'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see SANIONA AB (PUBL) (30S) total assets.
Liquidity & Leverage Metrics
SANIONA AB (PUBL) Total Liabilities Ratios Explained
SANIONA AB (PUBL) total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 13.48 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.07 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.07 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how SANIONA AB (PUBL)'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for SANIONA AB (PUBL) (2021–2025)
The table below shows the annual total liabilities of SANIONA AB (PUBL) from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €44.58 Million ≈ $52.12 Million |
-58.69% |
| 2024-12-31 | €107.92 Million ≈ $126.16 Million |
+25.36% |
| 2023-12-31 | €86.08 Million ≈ $100.64 Million |
-14.76% |
| 2022-12-31 | €100.99 Million ≈ $118.07 Million |
-36.18% |
| 2021-12-31 | €158.25 Million ≈ $185.01 Million |
-- |
About SANIONA AB (PUBL)
Saniona AB (publ), a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of treatments for rare disease patients in Sweden, the United States, Germany, Denmark, and the United Kingdom. It also develops medicines modulating ion channels. The company's product includes Tesofensine, a monoamine reuptake inhibitor that has completed Phase 3 clinical t… Read more